+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function

  • PDF Icon

    Report

  • 300 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553709
Therapeutic Proteins Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global therapeutic proteins market as it emerges from the Covid 19 shut down.



Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the therapeutic proteins? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Therapeutic Proteins Market Global Report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers

Scope


Markets Covered:


1) By Product Type: Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle Stimulating Hormone
2) By Application: Metabolic Disorders; Immunologic Disorders; Hematological Disorders; Cancer; Hormonal Disorders; Genetic Disorders; Others
3) By Function: Enzymatic and Regulatory Activity; Special Targeting Activity; Vaccines; Protein Diagnostics

Companies Mentioned: Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche Ltd

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Therapeutic Proteins Market

What is the estimated value of the Global Therapeutic Proteins Market?

The Global Therapeutic Proteins Market was estimated to be valued at $112.2 billion in 2022.

What is the growth rate of the Global Therapeutic Proteins Market?

The growth rate of the Global Therapeutic Proteins Market is 12.1%, with an estimated value of $177.3 billion by 2026.

What is the forecasted size of the Global Therapeutic Proteins Market?

The Global Therapeutic Proteins Market is estimated to be worth $177.3 billion by 2026.

Who are the key companies in the Global Therapeutic Proteins Market?

Key companies in the Global Therapeutic Proteins Market include Abbott Laboratories, Amgen inc., Baxter International inc., Eli Lilly and Company, F.Hoffmann, La Roche Ltd., Pfizer inc., Johnson & Johnson and Novo Nordisk A/S.

Table of Contents

1. Executive Summary2. Therapeutic Proteins Market Characteristics3. Therapeutic Proteins Market Trends And Strategies4. Impact Of COVID-19 On Therapeutic Proteins
5. Therapeutic Proteins Market Size And Growth
5.1. Global Therapeutic Proteins Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Therapeutic Proteins Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Therapeutic Proteins Market Segmentation
6.1. Global Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone
6.2. Global Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others
6.3. Global Therapeutic Proteins Market, Segmentation By Function, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Enzymatic and Regulatory Activity
  • Special Targeting Activity
  • Vaccines
  • Protein Diagnostics

7. Therapeutic Proteins Market Regional And Country Analysis
7.1. Global Therapeutic Proteins Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Therapeutic Proteins Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Therapeutic Proteins Market
8.1. Asia-Pacific Therapeutic Proteins Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Therapeutic Proteins Market
9.1. China Therapeutic Proteins Market Overview
9.2. China Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Therapeutic Proteins Market
10.1. India Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Therapeutic Proteins Market
11.1. Japan Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Therapeutic Proteins Market
12.1. Australia Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Therapeutic Proteins Market
13.1. Indonesia Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Therapeutic Proteins Market
14.1. South Korea Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Therapeutic Proteins Market
15.1. Western Europe Therapeutic Proteins Market Overview
15.2. Western Europe Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Therapeutic Proteins Market
16.1. UK Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Therapeutic Proteins Market
17.1. Germany Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Therapeutic Proteins Market
18.4. France Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Therapeutic Proteins Market
19.1. Eastern Europe Therapeutic Proteins Market Overview
19.2. Eastern Europe Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Therapeutic Proteins Market
20.1. Russia Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Therapeutic Proteins Market
21.1. North America Therapeutic Proteins Market Overview
21.2. North America Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Therapeutic Proteins Market
22.1. USA Therapeutic Proteins Market Overview
22.2. USA Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Therapeutic Proteins Market
23.1. South America Therapeutic Proteins Market Overview
23.2. South America Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Therapeutic Proteins Market
24.1. Brazil Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Therapeutic Proteins Market
25.1. Middle East Therapeutic Proteins Market Overview
25.2. Middle East Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Therapeutic Proteins Market
26.1. Africa Therapeutic Proteins Market Overview
26.2. Africa Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Therapeutic Proteins Market Competitive Landscape And Company Profiles
27.1. Therapeutic Proteins Market Competitive Landscape
27.2. Therapeutic Proteins Market Company Profiles
27.2.1. Abbott Laboratories
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Amgen Inc
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Baxter International Inc
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Eli Lilly and Company
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. F. Hoffmann-La Roche Ltd
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Therapeutic Proteins Pipeline Analysis29. Key Mergers And Acquisitions In The Therapeutic Proteins Market30. Therapeutic Proteins Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novo Nordisk A/S and Sanofi.

The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to $112.17 billion in 2022 at a compound annual growth rate (CAGR) of 12.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $177.30 billion in 2026 at a CAGR of 12.1%.

The therapeutic proteins market consists of sales of therapeutic proteins. Therapeutic proteins provide important therapies for diseases such as diabetes, cancer, infectious diseases, hemophilia, and anemia.

The main types of products in therapeutic proteins are insulin, fusion protein, erythropoietin, interferon, human growth hormone and follicle stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual 's primary anabolic hormone. It affects fat, carbohydrate and protein metabolism by boosting glucose uptake from the blood into the fat, liver and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, protein diagnostics and is used in various applications such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Advance technologies for protein-based drug development drives the therapeutic proteins market. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, coagulation factor IX recombinant human are some therapeutic protein drugs developed using protein engineering technologies approved by FDA in the past five years.

Increasing biosimilar drugs in global market decline the growth of the therapeutic proteins market. Patent expiry of therapeutic proteins such as monoclonal antibodies give space for entry of biosimilar. In EU, AbbVie evidenced patent expiration of Humira (adalimumab) in 2018, five biosimilar of Humira from Mylan, Amgen, Sandoz, Samsung Bioepis received drug approvals from European commission to enter the EU market. These cost-effective treatments similar to original biologics decline the revenue and sales of therapeutic proteins.

Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer, immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are dominant and well-established product class in the protein therapeutic segment with more safety and immunogenicity than antibodies. Cell-based expression systems such as Chinese hamster ovary (CHO) mammalian cell expression system with latest technologies increased the productivity of monoclonal antibodies by overcoming the problems associated with earlier antibody drugs. In last five years, FDA approved 213 drugs, among them 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders.

In the United States, therapeutic protein drug manufacturers file therapeutic biologics application (BLA) to FDA for the product approvals. The drug approved through BLA should be proved as safe, pure and potent. FDA consolidated review of most therapeutic proteins in Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company acquired Protomer Technologies Inc. for $ 1 billion. Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin programme, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specializes in next-generation protein therapies which can detect molecular activators in the body that are being developed.

The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Amgen inc.
  • Baxter International inc.
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Pfizer inc.
  • Johnson & Johnson
  • Merck & Co. inc.
  • Novo Nordisk A/S
  • Sanofi
  • Biogen inc.
  • Genentech inc.
  • Generex Biotechnology
  • Genetech
  • Merck Serono S.A
  • AstraZeneca
  • Boehringer Ingelheim
  • Chugai Pharmaceutical
  • Diasome Pharmaceuticals
  • GeneScience Pharmaceuticals
  • Hualan Biological Engineering
  • CSL Behring
  • Kyowa Hakko Kirin
  • Oramed Pharmaceuticals
  • Sandoz International
  • Teva Pharmaceutical Industries
  • AbbVie
  • Bristol Myers Squibb Co.
  • Novartis
  • ProBiogen AG

Methodology

Loading
LOADING...